espite major therapeutic advances, the public health burden associated with coronary heart disease (CHD) remains enormous with approximately 525 000 people predicted to have a new myocardial infarction (MI) in 2013, %15.4 million estimated to be living with CHD in 2013, and %1 346 000 people hospitalized in 2009 for CHD.
D
espite major therapeutic advances, the public health burden associated with coronary heart disease (CHD) remains enormous with approximately 525 000 people predicted to have a new myocardial infarction (MI) in 2013, %15.4 million estimated to be living with CHD in 2013, and %1 346 000 people hospitalized in 2009 for CHD. 1 There are a variety of ways to measure the population impact of a disease including prevalence, associated morbidity and mortality, quality of life, health care utilization, and economic costs, and one of the most critical is disease incidence. From a surveillance perspective in the United States, the national vital statistics data system provides information about the death rate for CHD, various national data systems provide estimates of hospitalizations for CHD and outpatient visits for CHD, and national data systems provide data about levels of risk factors for CHD. The data systems allowing for estimates of prevalent CHD are less robust as they rely primarily on self-reported information.
A particularly glaring gap in our knowledge base has been the lack of nationally representative data to measure the incidence of CHD. Measuring incidence of a disease is particularly salient because incidence (1) is a key measure in helping to define the burden of a disease and identify high-risk populations, (2) provides valuable information in helping decision makers set public health priorities, and (3) is a more relevant measure to assess the collective influence of risk factors in a population than prevalence. Consequently, tracking incidence of a disease in populations can: (1) yield timely data about potentially unfavorable changes in incidence that may prompt a search for explanations and corrective actions to redirect the course of a disease in a population, (2) provide valuable feedback in assessing efforts to control a disease, and (3) generate useful information for updating priorities regarding health promotion and disease prevention. The reasons why a national surveillance system to track CHD incidence in the United States has never been developed are not entirely clear but may relate to the cost and complexity of implementing such a system.
Our objective is to review the fragmented data that may have bearing on incidence of CHD in the United States. Because national data about incident CHD are not readily available, we will examine various facets of CHD epidemiology-including mortality, hospitalizations and case-fatality, prevalence, risk factors, and predicted risk-that may provide insights about national trends in the incidence of CHD. Incidence, prevalence, and mortality are interrelated, 2, 3 and, hence, we will explore data for the latter two important population surveillance parameters. Declining mortality rates have been postulated as possible evidence for declining incidence rates, and, therefore, we examine published trends in mortality as well as in case-fatality rates that have bearing on overall mortality rates from CHD. Furthermore, trends in hospitalizations for MI have often been used as a surrogate measure for trends in incidence of this condition, and consequently, we review national and regional data on this topic. Because the sum total of risk factors for CHD drive the incidence of this disease, we assess trends in individual risk factors as well as predicted risk calculated from major CHD risk factors. Finally, we review regional data about trends in CHD incidence from community surveillance and cohort studies.
Mortality
The category "diseases of the heart" has long been and continues to be the leading cause of death in the United
States based on data from death certificates. 4 After increasing during the first part of the 20th century, the mortality rate attributed to CHD peaked during the late 1960s and reversed course starting a prolonged and continuing decline. 5, 6 From 1980 through 2009, ageadjusted CHD mortality has decreased by 66% among men and 67% among women ( Figure 1 ). Furthermore, ageadjusted rates decreased by 60% among African American women, 57% among African American men, 68% among white women, and 67% among white men ( Figure 2 ). CHD mortality was defined as International Classification of Diseases (ICD)-9 codes 410-414 and 429.2 or ICD-10 codes I20-I25. Regional studies such as the Framingham Heart Study, the Minnesota Heart Survey, Honolulu Heart Program, and the Atherosclerosis Risk in Communities Study (ARIC) also described declining rates of CHD mortality. [7] [8] [9] [10] [11] The factors contributing to the decline have been debated, and a combination of treatment and improvements in population levels of risk factors for CHD has been credited with lowering the CHD mortality rate. [12] [13] [14] [15] [16] [17] The declining mortality rates raised the prospect of declining incidence rates. Because mortality rates are subject to a number of influences such as disease severity, case fatality, changes in risk factors, improved treatment, and incident or new cases, 18 declining mortality rates alone cannot automatically be equated with declining incidence rates.
Hospitalizations
Several large data sets have provided information about trends in hospitalizations for MI (Table 1) . Based on the Acute Care Tracker data base, a proprietary administrative database that included 458 US hospitals, rates of hospitalization for MI based on principal diagnosis ICD-9 codes decreased from 309 in 2002 to 266 per 100 000 population in 2005. 19 The numbers of total discharges and coronary revascularizations compared reasonably well with estimates from the National Hospital Discharge Survey, but the diagnoses of MI were not specifically validated. An analysis of data from the National Hospital Discharge Survey showed that the rate of hospitalizations for MI using the first-listed diagnosis code increased from 215 in 1979--1981 to 342 per 100 000 population in 1985--1987, remained relatively level until 1996, and then declined to 242 per 100 000 population in 2003--2005. 20 No validation of discharge diagnoses was done. The rate of hospitalizations for MI using principal diagnosis codes 400   500   600   700   800   1979  1980  1981  1982  1983  1984  1985  1986  1987  1988  1989  1990  1991  1992  1993  1994  1995  1996  1997  1998  1999  2000  2001  2002  2003  2004  2005  2006  2007  2008 Discharge diagnoses were not validated. An analysis of data from the National Inpatient Sample of the Healthcare Cost and Utilization Project from 2001 to 2007 found that the rate of hospitalization from MI based on the principal diagnosis dropped from 314 to 222 per 100 000 population, and decreases were observed in most demographic subgroups. 22 The validity of the discharge diagnoses over time remained untested in this data set. However, these studies were not able to identify incident CHD or to examine the impact of changes in diagnostic criteria for MI on hospitalization rates. Furthermore, validation of hospitalizations for MI diagnostic codes has generally not been done in these studies.
Case-Fatality
Several measures of case-fatality rates can be conceptualized in terms of time frame: in-hospital mortality, 28-or 30-day mortality, and 1-, 2-, 3-, and 5-year mortality (Table 2) . 400   500   600   700   800   1979  1980  1981  1982  1983  1984  1985  1986  1987  1988  1989  1990  1991  1992  1993  1994  1995  1996  1997  1998  1999  2000  2001  2002  2003  2004  2005  2006  2007  2008 Table 2 . Numerous publications have documented improvements in the in-hospital or short-term case-fatality rate. 7,11,18,20, An early report from the Worcester Heart Attack Study failed to observe improved post-discharge long-term survival in patients who sustained an MI in 1975 MI in , 1978 MI in , or 1981 . 40 A subsequent analysis of data from this study again failed to find improvements in 1-, 2-, and 5-year survival rates for patients who were discharged during 1975-1978, 1981-1984, 1986-1988, and 1990-1991 . 27 More recently, To examine the recent trend in CHD prevalence, we used NHANES data of adults aged ≥20 years from 1999 to 2012 (Table 3) . 43 CHD was defined as ever having been told by a doctor or other health professional that the participant had CHD, angina pectoris, or a heart attack. The unadjusted prevalence showed little change during the 10-year period.
After adjustment for age, the prevalence of CHD increased from 6.3% during 1999-2000 to 6.9% during 2003-2004 and then decreased to 5.2% during 2009-2012, and the overall trend showed a decrease (P for linear trend=0.001). Furthermore, decreases in the age-adjusted prevalence of selfreported CHD were noted for men, women, whites, African Americans, adults who had not completed high school or with education beyond high school, adults without diagnosed diabetes, and adults with a body mass index <30 kg/m 2 .
Based on data from the NHIS from 1980 to 1989, the age-adjusted prevalence of self-reported CHD among US adults aged 45 to 84 years varied between 2.2% and 2.6% with no clear trend. 44 Recent data from the BRFSS showed that the prevalence of self-reported CHD declined from 6.7% in 2006 to 6.0% in 2010 in adult populations aged ≥18 years. 45 Declines were noted in all age groups, men and women, all education groups, and among whites and Hispanics but not among blacks, Asians or Native Hawaiians/Other Pacific Islanders, and American Indians or Alaska Natives.
In several NHANES, electrocardiograms (ECGs) were administered to adults aged 40 to 74 years. However, recent NHANES have not included this component. The percentages of adults with possible or probable ECG-defined MI were 3.6% during 1971-1975, 3.4% during 1976-1980 , and 2.4% during 1988-1994. 41 Among successive groups of Framingham Study participants who were aged 55 to 64 years in 1953, 1963, and 1973 , the prevalence of CHD among men increased from 10.2% in 1953 to 15.9% in 1973 (P=0.003) and that among women from 5.5% in 1953 to 6.9% in 1973 (P=0.250). 46 CHD was defined as MI, coronary insufficiency, angina pectoris, and sudden and non-sudden death from CHD. Period prevalence of MI (hospitalization for MI or an out-ofhospital death due to MI) in the Pee Dee area of South Carolina decreased from 642 per 100 000 population in 1978 to 469 per 100 000 population in 1985. 26 This overall trend reflected a significant decrease among white men, nonsignificant decreases among black men and women, and a nonsignificant increase among white women. A series of autopsy studies from Olmsted County, Minnesota provide an interesting perspective on the trend in the 54 In addition, control of hypercholesterolemia has also improved. 55 The trend in hypertension has been more complicated. Thus, providing an integrated picture of all these possible first occurrences of CHD would require a system that is able to capture the spectrum of disease expression. However, such a system does not currently exist at the national level. Because national data about incident CHD are not available, our current knowledge of the true incidence of CHD in the United States comes from an amalgam of community surveillance (Table 4) , cohort studies (Table 5) , and health care delivery systems. Each of these sources of information has, to a variable degree, limitations that may include time frames, geographic coverage, and generalizability of the study populations.
Community surveillance
One of the earliest studies to examine trends in the incidence of CHD emanated from Rochester, Minnesota. 34 When MI hospitalizations were restricted to those that used creatine kinase/creatine kinase-MB but not troponin for the diagnosis of MI, a significant decrease in the rate from 186 to 141 was observed. Furthermore, rates of STEMI declined significantly by 41% when troponin was considered or 44% when troponin was excluded. However, rates of incident NSTEMI increased by 49%. An interesting aspect of this study is that measurements of creatine kinase/creatine kinase-MB continued to be administered from 2000 on as troponin was being ushered These changes were not statistically significant. From 1988 to 1992, the age-adjusted incidence rates of hospitalized MI in the Corpus Christi Heart Project decreased significantly among Mexican-American women. 76 Nonsignificant reductions were reported for white women and Mexican-American men, and little change was reported for white men.
In Seattle, the age-and sex-adjusted incidence rates of cardiac arrest with ventricular fibrillation from 1980 to 2000 declined by 56%, and the incidence of all treated arrests declined by 34%. 77 Declines in the incidence rates of cardiac arrest with ventricular fibrillation were similar for men and women, but the decline in the incidence rates of all treated arrests in men exceeded that in women.
As part of the ARIC study, surveillance of hospital admissions for MI among residents aged 35 to 74 years In Milwaukee, the incidence (per 100 000) of treated cardiac arrest with ventricular fibrillation or tachycardia as the first recorded rhythm declined from 37.1 in 1992 to 19.4 in 2002. 78 The incidence of all treated arrests was 82.8 in 1992
and 82.3 in 2002. These community surveillance studies provide strong evidence that incidence has decreased in those areas although the onset of the decline varied by geographical location with the earliest decline being observed in Olmsted County, Minnesota. These well-conducted studies employed standardized case-definitions for MI. Two of these studies also carefully navigated the changing currents in diagnostic criteria for MI. Nevertheless, a drawback of these studies remains their narrow geographic focus.
Cohort studies
A study of male employees of Du Pont Company showed that the age-adjusted incidence rate (per 1000) of first MI decreased steadily from 3.19 during 1957-1959 to 2.29 during 1981-1983. 24 Events were identified from insurance claims and death certificates, and medical records were reviewed. In a cohort of 8006 men of Japanese ancestry living on Oahu, the incidence of CHD increased from 1966 to 1978 and then decreased through 1984. 9 For the entire study period, the estimated annual change in incidence was À0.4% (95% CI: À2.6%, +1.8%). Incident CHD events included CHD deaths (ICD-8 codes 410-414 as the underlying or contributing cause of death or sudden unexplained deaths within 1 hour of being well) and nonfatal MI (ECG evidence and/or cardiac enzyme changes). An early analysis of data from the Framingham Heart Study found that the incidence of CHD among 3 successive cohorts of men and women aged 55-64 years did not change significantly from 1953-1963 to 1973-1983 . 46 For men, 38) . CHD was defined as MI, coronary insufficiency, angina pectoris, and sudden and non-sudden death from CHD. MI was determined from serial ECG changes and cardiac enzymes when they became available.
In a subsequent analysis of data from the Framingham Heart Study, 20-year incidence of CHD in 3 consecutive cohorts of adults aged 50 to 59 years was examined. 10 CHD included MI, angina, sudden and non-sudden coronary death, and coronary insufficiency. Among women, the incidence (per 1000) of CHD decreased significantly from 218 events in the 1950 cohort to 175 events in the 1970 cohort (P<0.05). In contrast, the rate among men was 354 in the 1950 cohort and 346 in the 1970 cohort. Another analysis of data from the Framingham Heart Study and Framingham Heart Study Offspring Cohort found that the risk of sudden coronary death in adults without CHD or congestive heart failure decreased by 39% from 1950-1969 to 1990-1999. 80 More recently, data from the Framingham Heart Study and Framingham Heart Study Offspring Cohort showed that the incidence of MI had declined during successive decades starting with 1960-1969 and ending with 1990-1999. 31 Among 9824 participants aged 40 to 89 years, 941 MIs were recorded of which 639 were defined on the basis of ECG changes and 302 on the basis of biomarker changes. MIs were identified by information obtained from study participants during follow-up examinations or mailings of update questionnaires and evaluated with medical records. MIs were divided into 2 groups: those with ischemic chest discomfort and diagnostic ECG changes irrespective of diagnostic biomarker changes (MI-ECG) and those with ischemic chest discomfort and diagnostic biomarker changes without diagnostic ECG changes (MI-marker). Rates of incident MI-ECG dropped by about half, whereas rates of incident MI-marker doubled. Significant decreases in MI-ECG were noted for men aged 50 to 59 years and 70 to 79 years as well as women aged 70 to 79 years. In contrast, significant increases in ECGmarker were noted for men aged 50 to 59 years and 70 to 79 years as well as women aged 70 to 79 years. The authors concluded that much of the uncertainty in trends in the incidence of MI may have been attributable to changes in diagnostic criteria for MI.
Data from the Nurses' Health Study that included 85 941 participants aged 34 to 59 years showed that the incidence of CHD declined by 31% from 1980-1982 to 1992-1994 . 79 CHD was defined as nonfatal MI or fatal coronary disease. The former was determined from medical record review of MIs reported by the study participants, and MI was defined using World Health Organization criteria. Deaths were determined from state vital records, the National Death Index, reports by next of kin, and the postal system. In all, 946 participants had a nonfatal MI and 358 experienced death attributable to coronary disease. An analysis of data from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study from 1971 to 1992 showed that the age-adjusted incidence (per 10 000) declined from 133. 3 from 1971-1975 to 1982-1984 to 113.5 from 1982-1984 to 1992 for CHD and from 49.7 to 49.2, respectively, for MI. 28 The incidence of CHD declined significantly among white men (À14.6%) and women (À11.4%). The relative decrease among black men (À18.5%) was the largest of the 4 groups but failed to reach statistical significance. The decrease among black women (À3.8%) was the smallest of any of the 4 groups. The baseline cohort included 10 869 participants aged 35 to 74 years, and the follow-up cohort included 9774 participants aged 35 to 74. Incident CHD was defined as a death from CHD, a hospitalization for CHD, or a nursing home stay with the ICD-9 codes of 410-414. Prevalent CHD was excluded from the baseline cohort on the basis of self-reported heart attack, heart failure, or stroke as well as the use of medications used to treat heart disease. The cohort studies provide valuable insights into trends of incident CHD in their study populations, which range from relatively specific populations such as employees of a company to near representative samples of US adults. Thus, generalizability of their findings to the national level is a prime limitation. Also, the age range of participants of many cohort studies is limited precluding an examination of trends in incidence across the full adult lifespan. By examining the experience of the participants who have been repeatedly examined, a Hawthorne-type of effect could be introduced into studies in that study participants may alter their behaviors in response to their study participation. On the other hand, cohort studies often use some of the bestvalidated measures of incident CHD and yield information over some of the longest time frames.
Health care delivery systems
The large health care delivery systems potentially represent an important opportunity for conducting surveillance of CHD in large segments of the US population. Drawing from the administrative systems of Kaiser Permanente Northern California, investigators identified hospitalizations for MI from 1999 to 2008 using the ICD-9-CM code of 410 and divided these into hospitalizations for STEMI (ICD-9-CM codes 410.0-410.6, 410.8) and NSTEMI (410.7, 410.9). 33 A total of 46 086
hospitalizations for incident MI among adults aged ≥30 years were included in the analyses. The age-and sex-adjusted rate (per 100 000 person-years) of hospitalizations for incident MI were 274 in 1999 and 287 in 2000 and then progressively declined to 208 through 2008. Rates of STEMI decreased steadily throughout the study period from 133 to 50, but the rates of NSTEMI increased until 2004 and began to decrease in subsequent years. Validation studies were performed to show that the positive predictive value for the STEMI and NSTEMI coding algorithm did not materially change during the study period. Because health care delivery systems represent an important source of health care and coverage, the databases and expanding rich electronic medical records of these health systems contain potentially valuable information about trends in the incidence of CHD of their memberships. However, information from these data systems is subject to several considerations: data from these plans generally may not reach back far in time, the need to validate electronic data sources deserves careful consideration, and health care delivery systems may not be fully representative of all relevant populations (eg, uninsured persons).
Population surveys
Data from the National Health Interview Survey have been analyzed to examine trends in the incidence of CHD. 44 Participants who reported that they had CHD, angina pectoris, myocardial infarction, or heart attack with an onset during the 12 months prior to their interview were considered to have had an incident event. From 1980 to 1989, the age-adjusted incidence per 1000 population ranged between 2.2 and 3.2 with no significant linear trend. Among white men, a nonlinear trend was described with decreasing rates from 1986 to 1989. Among white women, a significant increase in the incidence rate was observed. 34 Furthermore, the decline in hospitalizations for incident STEMI not paralleled by a similar decline in NSTEMI in the Kaiser Permanente Northern California system argues for a decline in the severity of MI. 33 Because severity of an MI reflects a complex mix of pathophysiologic underpinnings, patient behavior in seeking medical care, comorbidities, and medical care, studying temporal trends in severity is a complicated endeavor. 89, 90 Nevertheless, the available evidence suggests some degree of concordance between improving trends in MI severity and incident CHD.
Unrecognized MI

Summary and Closing Thoughts
Although a complete picture of the national trend in CHD incidence in the United States remains elusive, the findings from community-based studies, prospective studies, and health care delivery systems reporting decreases in incidence of CHD provide the most convincing evidence that the national incidence of CHD may have declined. These findings are buttressed by data showing declines in national rates of death attributed to CHD, studies showing decreases in sudden death and out-of hospital mortality associated with MI, declines in hospitalizations for CHD, improving MI severity, possible recent declines in prevalence of CHD, declines in predicted 10-year risk, and favorable improvements in the prevalence and control of some major CHD risk factors. Although each of these pieces of information is an imperfect reflection of incident CHD, in the aggregate they tell an increasingly compelling story of the evolution of CHD incidence in the United States. Declines in death from CHD are potentially suggestive of declining CHD incidence if the declines in case-fatality rates do not account for the entire decrease in mortality.
Because the studies examining trends in CHD incidence covered different time frames and were conducted in different areas of the United States, pinpointing the exact time when incidence started to decrease is difficult because the onset of the start of any declines may have varied geographically. Community surveillance studies have reported decreases in incidence as early as the 1960s (Rochester, MN), 7 during the late 1980s (Corpus Christi Heart Project), 76 1990s (ARIC), 38 and 2000s (Worcester Heart Attack Study). 32 Other studies suggest that decreases in incidence occurred during the 1960s (Framingham Heart Study, the Du Pont Company), Three of the studies illustrate the difficulty in interpreting surveillance data over long periods of time particularly when changes in diagnostic criteria occur. 31, 34, 38 The introduction of troponin testing around the turn of the century marked an important change in the diagnostic criteria for MI 91 and coincided with a shift in the ratio of STEMI to NSTEMI with decreases in rates of STEMI and increases in rates of NSTEMI. Furthermore, the advent of electron-beam computed tomography and multi-detector computed tomography to detect calcium in the walls of coronary arteries has led to earlier identification of CHD. 92 From a surveillance point of view, these disruptive changes in diagnostic criteria emphasize the importance of being able to disentangle the effects on such changes on trend analyses. Validation of incident CHD events enhances the credibility of trends in CHD incidence. The majority of community surveillance, cohort, and health care delivery system-based studies included reviews of medical records searching for clinical presentation, electrographic criteria, and cardiac biomarkers to confirm the presence of CHD, although these validation efforts differed across studies and across time periods as diagnostic criteria were also evolving.
Furthermore, observational studies suggest that an enormous amount of CHD can yet be prevented by adopting healthy behaviors or by optimizing behavioral and clinical risk factors as exemplified by the AHA's 7 cardiovascular health metrics. [93] [94] [95] [96] [97] [98] [99] In addition, initiatives such as the Million Hearts
Initiative, which aims to prevent 1 million heart attacks and strokes by 2017 through a combination of clinical and community actions, will, if successful, potentially hasten the decline in the incidence of CHD. 100, 101 The data sources opening a window into race or ethnicityspecific trends of CHD incidence are few. Data from the ARIC study suggest that African-American men and women did enjoy declining CHD incidence, but the decline among African Americans manifested itself later than among whites and the size of the decline was smaller than that of whites. These results are corroborated by Medicare data and data from the NIS also showing that the hospitalization rate for MI declined more slowly among African Americans than among whites. 21, 22 Gaps in evidence exist about the trends in CHD incidence among other racial or ethnic groups such as Hispanics and Asians. Given the rapidly evolving demographic composition of the US population, data collection efforts to shed light on the evolution of CHD in major and growing racial and ethnic groups are needed. Perhaps, large health care delivery systems and growing health system-based networks are best suited to provide such results if their expanding electronic medical record and other data systems capture valid racial and ethnic designations and relevant clinical outcomes of their memberships. Efforts to establish community surveillance for CHD harken back decades. 102, 103 A national system to monitor CHD incidence has never been established, however, and this gap has not gone unnoticed. [104] [105] [106] [107] As part of its recommendations, the Institute of Medicine highlighted the critical importance of having data on the incidence of CVD and the need for a system that would collect such data. The report cited potential avenues such as the establishment of registries, the use of cohort studies, and the use of claims and electronic medical record data to accomplish such a goal. The development of a national system to monitor the trend in the incidence of CHD would help to fill this current void in the knowledge base of the epidemiology of CHD and provide critical data to improve cardiovascular health of the US population.
In conclusion, definitive data about national trends of incident CHD in the United States currently are not available, and, therefore, clues about these trends must be gleaned from a variety of auxiliary data sources. Studies in different parts of the country demonstrate improvements in the incidence of CHD that may have commenced several decades ago in some parts of the country, and an increasing number of recent studies have described favorable trends during the first decade of the 21st century. Taken together, these studies yield encouraging but tentative signals that the incidence of CHD in the United States may be waning. Bringing greater clarity to this important topic of cardiovascular epidemiology poses a pressing public health need.
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